Table 3 Standardized mortality ratio... | American Society of Hematology

Table 3

Standardized mortality ratio (SMR) among 2-year survivors of allogeneic HCT

Variables	Entire cohort		Standard risk of relapse		High risk of relapse
Variables	No. of deaths	SMR (95% CI)	No. of deaths	SMR (95% CI)	No. of deaths	SMR (95% CI)
All patients	241	9.9 (8.7-11.2)	152	8.4 (7.1-9.8)	88	14.5 (11.7-17.7)
Sex
Male	147	8.2 (6.9-9.6)	97	7.4 (6.0-8.9)	50	10.8 (8.0-14.0)
Female	94	12.8 (10.3-15.5)	55	9.9 (7.4-12.6)	38	21.5 (15.2-28.9)
Age at transplantation, y
Younger than 18	63	16.5 (12.7-20.8)	48	14.6 (10.8-19.0)	15	28.8 (16.1-45.3)
18 to 45	150	9.1 (7.7-10.6)	92	7.7 (6.2-9.3)	57	12.9 (9.8-16.5)
Older than 45	28	7.1 (4.7-9.9)	12	4.2 (2.2-7.0)	16	14.2 (8.1-22.0)
Year of transplantation
1974 to 1979	15	9.4 (5.2-14.7)	13	9.4 (5.0-15.3)	2	13.4 (1.3-38.5)
1980 to 1984	49	7.9 (5.8-10.2)	34	7.4 (5.1-10.1)	15	9.2 (5.1-14.5)
1985 to 1989	63	10.5 (8.1-13.3)	39	8.9 (6.3-11.9)	24	15.0 (9.6-21.6)
1990 to 1994	71	11.2 (8.7-13.9)	49	10.2 (7.5-13.2)	21	13.8 (8.5-20.3)
1995 to 1998	43	10.5 (7.6-13.8)	17	5.8 (3.4-8.9)	26	22.5 (14.7-31.9)
Survival after diagnosis
2 to 5 y	149	77.5 (65.6-90.5)	92	73.5 (59.2-89.3)	57	85.0 (64.4-108.5)
6 to 10 y	50	8.3 (6.1-10.7)	29	6.3 (4.2-8.8)	20	13.9 (8.5-20.7)
11 to 15 y	21	3.7 (2.3-5.4)	15	3.7 (2.0-5.7)	6	3.6 (1.3-7.2)
16 to 20 y	20	2.9 (1.8-4.3)	15	3.0 (1.7-4.8)	5	2.5 (0.8-5.2)
21+ y	1	0.3 (0.0001-1.1)	1	0.3 (0.0001-1.2)	0	—
Chronic graft-versus-host disease
Yes	158	12.4 (10.5-14.4)	95	10.6 (8.6-12.9)	62	16.8 (12.8-21.2)
No	78	6.9 (5.4-8.5)	53	5.9 (4.4-7.6)	25	10.6 (6.9-15.2)
Primary diagnosis
AML	82	10.8 (8.6-13.3)	46	8.5 (6.2-11.1)	36	17.3 (12.1-23.5)
CML	74	8.2 (6.4-10.2)	41	6.8 (4.9-9.1)	33	11.0 (7.6-15.0)
ALL	46	12.8 (9.4-16.8)	32	10.9 (7.5-15.1)	14	21.0 (11.5-33.5)
NHL	10	12.5 (6.0-21.5)	4	8.5 (2.2-18.9)	5	16.1 (5.1-33.4)
SAA	17	5.7 (3.3-8.8)	17	5.7 (3.3-8.8)	0	—
IEM	12	36.7 (18.9-60.4)	12	36.7 (18.9-60.4)	0	—

Variables	Entire cohort		Standard risk of relapse		High risk of relapse
Variables	No. of deaths	SMR (95% CI)	No. of deaths	SMR (95% CI)	No. of deaths	SMR (95% CI)
All patients	241	9.9 (8.7-11.2)	152	8.4 (7.1-9.8)	88	14.5 (11.7-17.7)
Sex
Male	147	8.2 (6.9-9.6)	97	7.4 (6.0-8.9)	50	10.8 (8.0-14.0)
Female	94	12.8 (10.3-15.5)	55	9.9 (7.4-12.6)	38	21.5 (15.2-28.9)
Age at transplantation, y
Younger than 18	63	16.5 (12.7-20.8)	48	14.6 (10.8-19.0)	15	28.8 (16.1-45.3)
18 to 45	150	9.1 (7.7-10.6)	92	7.7 (6.2-9.3)	57	12.9 (9.8-16.5)
Older than 45	28	7.1 (4.7-9.9)	12	4.2 (2.2-7.0)	16	14.2 (8.1-22.0)
Year of transplantation
1974 to 1979	15	9.4 (5.2-14.7)	13	9.4 (5.0-15.3)	2	13.4 (1.3-38.5)
1980 to 1984	49	7.9 (5.8-10.2)	34	7.4 (5.1-10.1)	15	9.2 (5.1-14.5)
1985 to 1989	63	10.5 (8.1-13.3)	39	8.9 (6.3-11.9)	24	15.0 (9.6-21.6)
1990 to 1994	71	11.2 (8.7-13.9)	49	10.2 (7.5-13.2)	21	13.8 (8.5-20.3)
1995 to 1998	43	10.5 (7.6-13.8)	17	5.8 (3.4-8.9)	26	22.5 (14.7-31.9)
Survival after diagnosis
2 to 5 y	149	77.5 (65.6-90.5)	92	73.5 (59.2-89.3)	57	85.0 (64.4-108.5)
6 to 10 y	50	8.3 (6.1-10.7)	29	6.3 (4.2-8.8)	20	13.9 (8.5-20.7)
11 to 15 y	21	3.7 (2.3-5.4)	15	3.7 (2.0-5.7)	6	3.6 (1.3-7.2)
16 to 20 y	20	2.9 (1.8-4.3)	15	3.0 (1.7-4.8)	5	2.5 (0.8-5.2)
21+ y	1	0.3 (0.0001-1.1)	1	0.3 (0.0001-1.2)	0	—
Chronic graft-versus-host disease
Yes	158	12.4 (10.5-14.4)	95	10.6 (8.6-12.9)	62	16.8 (12.8-21.2)
No	78	6.9 (5.4-8.5)	53	5.9 (4.4-7.6)	25	10.6 (6.9-15.2)
Primary diagnosis
AML	82	10.8 (8.6-13.3)	46	8.5 (6.2-11.1)	36	17.3 (12.1-23.5)
CML	74	8.2 (6.4-10.2)	41	6.8 (4.9-9.1)	33	11.0 (7.6-15.0)
ALL	46	12.8 (9.4-16.8)	32	10.9 (7.5-15.1)	14	21.0 (11.5-33.5)
NHL	10	12.5 (6.0-21.5)	4	8.5 (2.2-18.9)	5	16.1 (5.1-33.4)
SAA	17	5.7 (3.3-8.8)	17	5.7 (3.3-8.8)	0	—
IEM	12	36.7 (18.9-60.4)	12	36.7 (18.9-60.4)	0	—

SMR indicates standardized mortality ratio; 95% CI, 95% confidence interval; and —, not applicable.

†

One subject with unknown disease status at the time of HCT was excluded from the analysis.

‡

One subject with unknown cGVHD status was excluded from the analysis.

View Large

This Feature Is Available To Subscribers Only